Bejescin®

Name of the medicinal product

□ Obetuzumab Beta Injection

Posology and method of administration

□ The recommended dose is 1000 mg administered intravenously, given on Day 1 of Week 1, 

   Week 3, Week 25 and Week 27.

   For patients with NMOSD, subsequent administrations shall be given once every 26 weeks;

   For patients with pMN, one dose shall be administered in Week 1 of the second year during

   follow-up treatment.

Therapeutic indications

□ This product is indicated for the treatment of adult patients with neuromyelitis optica spectrum 

   disorder (NMOSD) who are positive for anti‑aquaporin 4 (AQP4) antibodies. 

   And for adult patients with moderate-to-high risk primary membranous nephropathy (pMN) to 

   reduce proteinuria.

Special precautions for storage

□ Store and transport at 2 °C to 8 °C, protected from light.

□ Do not freeze.

    Do not shake.

Strength

□ 200 mg (8 mL) per vial

Shelf life

□ 18 months